Understanding Pancreatic Enzyme Replacement Therapy

Pancreatic enzyme replacement therapy (PERT) is a medical intervention designed to compensate for insufficient production of digestive enzymes by the pancreas. In individuals with exocrine pancreatic insufficiency (EPI), the pancreas fails to produce adequate levels of lipase, protease, and amylase — the three enzyme families responsible for breaking down fats, proteins, and carbohydrates, respectively. PERT involves oral administration of encapsulated, enteric-coated enzyme supplements that mimic the natural digestive process. These supplements are typically derived from porcine (pig) pancreas and are formulated to release active enzymes in the small intestine, where digestion and absorption predominantly occur.

The prevalence of EPI in the general population is estimated at 10–15%, but rates climb dramatically among specific patient groups, particularly those with pancreatic diseases and diabetes. PERT has been a standard of care for cystic fibrosis-related EPI for decades, but its application in diabetes management is still evolving. Understanding the full scope of PERT requires examining the physiology of digestion, the pathophysiology of enzyme deficiency, and the clinical evidence supporting replacement therapy.

What Are Pancreatic Enzymes?

Pancreatic enzymes are produced by acinar cells in the pancreas and secreted into the duodenum via the pancreatic duct. Each enzyme class targets a specific macronutrient: lipase digests dietary fats into fatty acids and monoglycerides; protease breaks proteins into peptides and amino acids; and amylase converts starches into simple sugars. When enzyme output falls below a critical threshold — often defined as fecal elastase-1 levels less than 200 µg/g — malabsorption occurs, leading to steatorrhea (fatty, foul-smelling stools), weight loss, and deficiencies in fat-soluble vitamins A, D, E, and K.

The pancreas secretes approximately 1.5–3 liters of enzyme-rich pancreatic juice daily. Under normal conditions, the reserve capacity of the pancreas is substantial; clinical signs of EPI typically do not appear until enzyme output drops below 10% of normal. This large functional reserve means that by the time symptoms emerge, significant pancreatic damage has already occurred. The three main enzyme classes work in concert: lipase is the most vulnerable to degradation and requires the most careful replacement, protease helps activate other pancreatic enzymes and prevents bacterial overgrowth, and amylase is generally less critical since salivary amylase also contributes to starch digestion.

Forms of PERT Available

Several branded formulations of PERT are available, each containing a standardized mixture of lipase, protease, and amylase. The most commonly prescribed products include Creon, Zenpep, and Pancreaze. All are encapsulated with enteric coating to protect enzymes from degradation by stomach acid. Differences among these products lie in the specific ratios of enzymes, the size of the beads (mini-microspheres vs. microtablets), and the lipase content per capsule, which can range from 3,000 to 36,000 USP units. Clinicians select a product and dose based on the patient's fat intake, degree of insufficiency, and personal tolerance.

Additional formulations include Pertzye, which contains a specialized enteric coating designed for enhanced duodenal release, and Viokace, a non-enteric-coated product that must be used in combination with a proton pump inhibitor to prevent gastric degradation. The choice between products often involves insurance formulary availability, patient preference regarding capsule size, and the presence of comorbidities such as gastroparesis, which may affect transit time and dissolution characteristics. For patients requiring very high lipase doses, selecting a product with higher lipase concentration per capsule can reduce pill burden and improve adherence.

How PERT Works

Enzymes must be taken with every meal and snack. The capsules are swallowed whole (or the contents can be sprinkled onto soft, acidic foods such as applesauce) and travel to the small intestine, where the enteric coating dissolves at a pH of approximately 5.5. Once released, the enzymes mix with chyme and catalyze the hydrolysis of nutrients. Adequate PERT results in normalized stool frequency and consistency, improved weight stability, and correction of nutritional deficiencies. Studies indicate that appropriate PERT can improve fat absorption rates from below 70% to above 90% in patients with EPI.

The pharmacokinetics of PERT are designed to match the physiological timing of digestion. The enteric coating prevents premature enzyme release in the acidic stomach environment, where pH ranges from 1.5 to 3.5. After gastric emptying, the duodenal pH rises to approximately 6.0 due to bicarbonate secretion from the pancreas and bile, triggering dissolution of the coating and rapid enzyme release. The microspheres or microtablets are designed to mix thoroughly with the chyme, ensuring uniform enzymatic activity throughout the digestive bolus. This mixing is critical because fat digestion requires emulsification and surface area contact between lipase and lipid droplets.

The Diagnostic Pathway for EPI

Diagnosing EPI involves a combination of clinical assessment and laboratory testing. The most widely used screening test is fecal elastase-1 (FE-1), a pancreatic enzyme that remains stable during intestinal transit and correlates with pancreatic function. An FE-1 level below 200 µg/g indicates moderate to severe EPI, while levels below 100 µg/g suggest severe insufficiency. However, FE-1 can yield false positives in conditions with watery diarrhea due to sample dilution, so confirmatory testing is sometimes warranted.

The gold standard for diagnosing EPI is the 72-hour fecal fat collection, where fat excretion exceeding 7 grams per day on a 100-gram fat diet confirms malabsorption. This test is cumbersome and rarely performed in routine practice but remains the reference standard in clinical trials. Other diagnostic tools include serum trypsinogen levels (low levels indicate reduced pancreatic mass), secretin-stimulated pancreatic function testing (direct measurement of ductal secretion), and imaging studies such as endoscopic ultrasound or MRI to assess pancreatic parenchymal changes. For diabetic patients, the diagnostic yield is highest when symptoms of malabsorption are present, but screening should also be considered in patients with unexplained weight loss or glycemic instability.

The pancreas serves a dual role: an endocrine function (insulin and glucagon secretion) and an exocrine function (digestive enzyme production). While diabetes management focuses on the endocrine pancreas, the exocrine component is often compromised, particularly in long-standing or poorly controlled disease. This bidirectional relationship — diabetes leading to exocrine insufficiency and vice versa — makes PERT a relevant, though frequently overlooked, tool in comprehensive diabetes care.

The structural and functional overlap between the endocrine and exocrine pancreas is not coincidental. Both arise from common progenitor cells during development, and the islets of Langerhans are embedded within the exocrine parenchyma. Blood flow within the pancreas proceeds from exocrine to endocrine tissue, meaning that hormones and inflammatory mediators produced in the acinar environment can directly influence islet cell function. This anatomical intimacy creates multiple pathways for disease propagation, where damage to one compartment inevitably affects the other.

Epidemiology of EPI in Diabetes

EPI is more prevalent in diabetes than in the general population. In type 1 diabetes, autoimmune destruction of beta cells often extends to acinar tissue, reducing enzyme output. In type 2 diabetes, chronic hyperglycemia, insulin resistance, and metabolic inflammation can damage pancreatic acinar cells. Longitudinal studies estimate that 30–50% of people with type 1 diabetes and 20–30% of those with type 2 diabetes have reduced fecal elastase levels, indicating some degree of EPI. These numbers rise sharply in individuals with diabetic gastroparesis or recurrent pancreatitis.

The duration of diabetes correlates positively with EPI prevalence. In a 2021 systematic review, the pooled prevalence of EPI was 33% among individuals with type 1 diabetes of more than 10 years duration, compared to 18% in those with shorter disease duration. For type 2 diabetes, the prevalence increases with age, disease duration, and the presence of metabolic syndrome components such as hypertriglyceridemia, which is itself a risk factor for pancreatitis. Importantly, EPI in diabetes is often mild to moderate rather than severe, meaning symptoms may be subtle and easily attributed to other causes. This pattern of subclinical insufficiency is precisely why PERT is underutilized — the condition is present but unrecognized.

Mechanisms of Enzyme Deficiency in Type 1 and Type 2 Diabetes

Several mechanisms explain exocrine insufficiency in diabetes. For type 1, autoimmune attack on beta cells may involve cross-reactivity with acinar cell antigens. For type 2, metabolic stress, oxidative damage from hyperglycemia, and altered enteropancreatic reflexes can impair enzyme synthesis. Additionally, long-term use of certain diabetes medications (e.g., GLP-1 receptor agonists) may slow gastric emptying and reduce duodenal stimulation of pancreatic enzyme secretion. In both types, autonomic neuropathy affecting the vagus nerve can also diminish the neural drive to release enzymes after a meal.

Beyond these direct mechanisms, several indirect pathways contribute to EPI in diabetes. Diabetic microangiopathy can reduce pancreatic blood flow, compromising acinar cell nutrition and function. Pancreatic fibrosis, observed in autopsy studies of long-standing diabetes, reflects cumulative acinar damage and replacement with fibrotic tissue. Altered gut hormone signaling, particularly reduced cholecystokinin (CCK) secretion in response to meals, diminishes the hormonal stimulus for pancreatic enzyme release. In type 2 diabetes specifically, hyperinsulinemia and insulin resistance may directly suppress acinar cell function through insulin receptor desensitization on pancreatic tissue. The net effect is a progressive decline in secretory capacity that parallels the decline in beta cell function.

Recognizing EPI in Diabetic Patients

Recognizing EPI in diabetic patients is critical but challenging, because symptoms often overlap with typical diabetic gastrointestinal complaints. Key warning signs include chronic greasy, floating stools (steatorrhea), unintentional weight loss despite adequate caloric intake, bloating and flatulence after meals, and cramping abdominal pain. Laboratory markers such as low fecal elastase-1 (less than 200 µg/g) and elevated fecal fat (greater than 7 g/day) confirm the diagnosis. Undiagnosed EPI can exacerbate glycemic variability because malabsorbed nutrients give erratic postprandial glucose responses.

Additional clues that should prompt EPI screening include unexplained deficiencies of fat-soluble vitamins (particularly vitamin D deficiency despite supplementation), osteoporosis or osteopenia out of proportion to diabetes duration, nocturnal diarrhea, and persistent foul-smelling flatulence. Patients may also report that their stools are difficult to flush or leave an oily film on the toilet water. In diabetic gastroparesis, the symptoms of early satiety, nausea, and vomiting can mask underlying EPI, leading to diagnostic delay. A structured symptom questionnaire, such as the Pancreatic Exocrine Insufficiency Questionnaire (PEI-Q), can help clinicians identify candidates for testing.

The Bidirectional Relationship

The relationship between diabetes and EPI is genuinely bidirectional. While diabetes causes exocrine damage, EPI can also contribute to diabetes pathogenesis. Malabsorption of incretin-stimulating nutrients reduces glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) secretion, impairing insulin release. Chronic malabsorption of amino acids necessary for glucagon synthesis can disrupt counterregulatory responses to hypoglycemia. Furthermore, the systemic inflammation associated with EPI-related malnutrition may worsen insulin resistance, creating a vicious cycle of metabolic deterioration.

In patients with chronic pancreatitis, the progression from EPI to diabetes is well-documented and termed pancreatogenic diabetes (Type 3c). This form of diabetes accounts for 5–10% of all diabetes diagnoses and is characterized by brittle glycemic control, high risk of hypoglycemia, and low insulin requirements. While most diabetes-related EPI is less severe than in chronic pancreatitis, the pathophysiological overlap suggests that even mild exocrine insufficiency can have clinically meaningful metabolic consequences. Recognizing this bidirectional relationship reframes PERT not as a digestive aid alone but as a metabolic therapy that supports both nutritional status and glycemic stability.

Clinical Benefits of PERT in Diabetes Management

Incorporating PERT into the diabetes care plan offers multiple benefits that extend beyond simple digestive relief. Improved nutrient absorption supports metabolic stability, reduces gastrointestinal distress, and may even help optimize glycemic control. The cumulative evidence from clinical studies, observational cohorts, and case series supports a role for PERT as an adjunctive therapy in diabetic patients with confirmed EPI.

Improved Nutrient Absorption and Weight Maintenance

Adequate digestion of fats and proteins is essential for maintaining lean body mass and preventing cachexia. In diabetic patients with EPI, PERT restores the capacity to absorb calories from meals, thereby halting unintended weight loss and supporting a healthy body mass index (BMI). This is especially important for individuals with type 1 diabetes, who may already be at risk for hypoglycemia if weight loss is rapid. By normalizing fat-soluble vitamin levels, PERT also reduces the risk of osteoporosis and neuropathy — both common diabetic complications.

Beyond weight maintenance, PERT improves the absorption of essential amino acids required for muscle protein synthesis. Sarcopenia is increasingly recognized as a complication of diabetes, driven by insulin resistance, chronic inflammation, and poor nutritional status. In patients with concurrent EPI, the inability to digest dietary protein compounds this risk. Clinical studies show that PERT increases serum albumin and prealbumin levels within 4–8 weeks of initiation, reflecting improved protein nutrition. For patients with diabetic nephropathy, adequate protein nutrition may help slow the progression of muscle wasting often seen in advanced chronic kidney disease. Additionally, restoration of fat absorption improves the bioavailability of omega-3 fatty acids, which have anti-inflammatory effects relevant to diabetic complications.

Impact on Glycemic Control

Incomplete digestion can lead to unpredictable nutrient delivery to the small intestine, causing erratic glucose absorption and postprandial hyperglycemia or delayed hypoglycemia. PERT standardizes the breakdown of carbohydrates, leading to a more predictable postprandial glucose curve. Several small clinical trials have reported reductions in HbA1c (by 0.3–0.6%) and fewer episodes of unexplained glycemic variability after initiating PERT in diabetic patients with confirmed EPI. These effects are thought to arise from better synchronized carbohydrate digestion and improved insulin sensitivity associated with reduced inflammatory markers.

The mechanism linking PERT to improved glycemia is multifaceted. First, consistent carbohydrate digestion produces a more predictable glucose absorption profile, allowing insulin dosing to match actual nutrient delivery. Second, improved fat digestion slows gastric emptying through the release of cholecystokinin and peptide YY, which delays carbohydrate absorption and blunts postprandial glucose spikes. Third, restoration of incretin secretion — gut hormones that potentiate insulin release — improves the efficiency of endogenous insulin secretion. Fourth, reduction of systemic inflammation lowers cytokine-mediated insulin resistance. A 2020 meta-analysis of PERT studies in EPI reported a mean reduction in fasting glucose of 15–20 mg/dL among diabetic participants, with the largest effects seen in those with the most severe exocrine insufficiency at baseline.

Reduction of Gastrointestinal Symptoms

One of the most immediate benefits of PERT is the relief of uncomfortable gastrointestinal symptoms. Bloating, excessive gas, and steatorrhea often diminish within days of starting therapy. For patients with diabetic gastroparesis — a condition that delays stomach emptying and can exacerbate malabsorption — PERT can be life-changing. Although PERT does not treat the gastroparesis itself, by ensuring that the limited amount of food that leaves the stomach is properly digested, patients often experience fewer bouts of nausea and vomiting.

Patient-reported outcomes consistently rank GI symptom relief as the most valued benefit of PERT. In a survey of 245 diabetic patients with EPI, 87% reported significant improvement in stool consistency within two weeks of starting therapy, and 73% reported resolution of bloating. These improvements translate into meaningful quality-of-life gains, including reduced anxiety about eating in social settings, fewer missed work days due to GI distress, and better dietary variety as patients regain the ability to tolerate fatty foods. For patients who have been living with chronic unexplained GI symptoms for years, the response to PERT can be particularly dramatic, with many reporting that they had forgotten what normal digestion felt like.

Potential Synergy with Insulin Therapy

The relationship between PERT and insulin therapy is complex but potentially synergistic. Improved fat digestion slows gastric emptying and dampens postprandial insulin requirements. At the same time, more predictable carbohydrate absorption reduces the risk of late-postprandial hypoglycemia that can occur when insulin is dosed for a meal that is only partially absorbed. Some clinicians report that patients on PERT require modestly lower insulin doses and experience a narrower glucose range. However, individual adjustments must be made under careful supervision.

In practice, patients starting PERT should be counseled that insulin requirements may change. The initial days of therapy often produce a stabilization of glucose patterns rather than a simple dose reduction. Patients using carbohydrate counting for mealtime insulin dosing may find that their insulin-to-carbohydrate ratio becomes more consistent as carbohydrate digestion normalizes. For patients using fixed-dose insulin regimens, the reduction in glycemic variability can reduce the frequency of both hyperglycemic and hypoglycemic excursions. Continuous glucose monitoring (CGM) data frequently show a decrease in the coefficient of variation (CV) of glucose levels, indicating more stable day-to-day control. This synergy highlights the importance of close communication between the patient and diabetes care team during the PERT initiation period.

Practical Considerations for PERT in Diabetes Care

PERT is not a one-size-fits-all treatment. Effectiveness depends on proper dosing, correct timing, and ongoing monitoring. All PERT products require a prescription and should be initiated and adjusted by a healthcare provider experienced in managing EPI. For diabetic patients, additional considerations arise from the need to coordinate PERT with glucose-lowering medications, meal timing, and lifestyle factors.

Proper Dosing and Administration

The lipase content determines the dose, as fat digestion is the hardest to restore. A typical starting dose is 500 to 1,000 USP units of lipase per gram of dietary fat consumed. For an average meal containing 30–50 g of fat, this translates to 15,000–50,000 units of lipase. Capsules should be taken with the first bite of the meal (not before or after). For snacks, half the meal dose suffices. Patients must swallow capsules whole or sprinkle contents onto soft, non-alkaline foods; chewing or crushing destroys the enteric coating, rendering the enzymes inactive.

Dosing precision requires patients to have a general understanding of the fat content in their meals. While exact gram counting is not necessary for most patients, developing a sense of which meals are high-, moderate-, or low-fat helps guide dose selection. Many patients find it helpful to start with a standard dose for their largest meal of the day and then adjust based on stool symptoms. For high-fat meals (e.g., restaurant meals, holiday dinners), the dose may need to be increased by 50–100%. For low-fat snacks such as fruit or vegetables, a minimal dose or no dose may suffice, depending on the individual's degree of insufficiency. Patients should be advised to keep a symptom diary during the first few weeks of therapy to identify the optimal dose for various meal types.

Timing Relative to Meals

Enzymes need to reach the small intestine simultaneously with the ingested meal. Because the enteric coat resists dissolution in the stomach, the capsules should be consumed no more than 10–15 minutes after the start of eating. Taking enzymes too early exposes them to prolonged gastric acid, which can degrade some unprotected enzyme molecules, while taking them too late reduces mixing with chyme. Patients with gastroparesis may benefit from dividing the dose — taking a portion at the start of the meal and the remainder midway through.

For patients using rapid-acting insulin analogs, coordinating PERT with insulin timing adds another layer of complexity. Ideally, the patient takes the first bite of the meal, administers the enzyme capsules, and then injects or delivers the insulin dose. This sequence ensures that enzyme release and insulin action are synchronized with nutrient absorption. Patients using insulin pumps may find it easier to deliver a dual-wave or square-wave bolus to match the delayed gastric emptying and slower nutrient absorption that can occur with EPI. Real-time CGM can provide immediate feedback on whether the timing of PERT and insulin is well-coordinated, allowing for adjustments within the same meal.

Monitoring Therapeutic Response

Clinical response is assessed through symptom resolution (normal stool form, no visible oil, reduced bloating) and improved nutritional parameters such as serum albumin, prealbumin, and vitamin levels. Fecal elastase-1 can be rechecked after stabilization to confirm correction. If steatorrhea persists, the lipase dose should be increased by 25–50% and reviewed after one month. Side effects are rare but may include nausea, abdominal cramps, or perianal irritation. High doses (above 10,000 units/kg/day) have been linked with fibrosing colonopathy in animal models, though this is extremely rare in adults.

Structured follow-up at 4–6 weeks after PERT initiation is essential to assess efficacy and make dose adjustments. During this visit, clinicians should review the stool diary, check weight trends, and evaluate glycemic metrics from glucometer or CGM downloads. Laboratory monitoring should include serum levels of vitamins A, D, E, and K, as well as zinc and magnesium, which are often low in EPI. For diabetic patients, monitoring of renal function is also important because PERT contains sodium and can theoretically affect fluid balance in patients with advanced nephropathy. Long-term monitoring at 6- to 12-month intervals is appropriate for stable patients, with more frequent follow-up if symptoms recur or if weight changes significantly.

Challenges, Risks, and Barriers to PERT Use

Despite its benefits, PERT is underutilized in diabetes care. Many clinicians attribute gastrointestinal symptoms to diabetes itself or to medication side effects instead of investigating EPI. Furthermore, the cost and need for lifelong adherence can be barriers. Patients must be counseled on the importance of taking enzymes with every meal, not just when symptoms are bothersome. Another challenge is ensuring compatibility with other oral medications, particularly acid-suppressing drugs like proton pump inhibitors, which raise gastric pH and may interfere with enteric coating dissolution. When PPI use is necessary, some clinicians recommend switching to a product with a higher proportion of mini-microspheres or adjusting the enzyme dose.

Underdiagnosis and Clinical Inertia

The most significant barrier to PERT use in diabetes is underdiagnosis of EPI. A survey of endocrinologists found that fewer than 20% routinely screen diabetic patients for exocrine insufficiency, even in those with unexplained GI symptoms. This clinical inertia stems from several factors: the overlap between EPI symptoms and diabetic gastropathy, the absence of EPI screening from standard diabetes guidelines, and the perception that PERT is a gastroenterology intervention rather than a metabolic therapy. Educational initiatives targeting both endocrinologists and primary care physicians are needed to raise awareness of the link between diabetes and EPI and to provide practical screening algorithms.

Adherence and Cost

PERT requires administration with every meal and snack, creating a substantial pill burden. For patients already managing multiple diabetes medications, the addition of several capsules per meal can feel overwhelming. Cost is another significant barrier; PERT products are expensive, and insurance coverage varies widely. Generic formulations are limited, and many patients face high copayments or prior authorization requirements. Patient assistance programs offered by manufacturers can help, but navigating these programs requires time and effort. For patients with limited health literacy or financial resources, adherence may be particularly challenging. Strategies to improve adherence include pillbox organization, reminder apps, simplifying dosing schedules by using higher-strength capsules, and providing written action plans for dose adjustment.

Drug Interactions and Adverse Effects

Allergic reactions are possible, especially in patients with known porcine protein hypersensitivity. Additionally, PERT can interact with calcium and iron supplements, reducing their absorption, so these should be taken at a different time from enzyme administration. The enteric coating of PERT products can also interact with medications that alter gastric pH. Proton pump inhibitors and H2 antagonists raise gastric pH, which may cause premature enzyme release in the stomach, reducing efficacy. Conversely, antacids containing magnesium or aluminum can interfere with enzyme activity if taken concurrently. Patients should be advised to space these medications by at least 2 hours from PERT administration.

Adverse effects of PERT are generally mild and dose-dependent. Nausea and abdominal cramping most often occur at initiation and resolve within the first week as the gastrointestinal tract adapts. Perianal irritation can occur with high doses due to residual active enzymes in the stool, and this may require dose reduction or the use of barrier creams. Serious adverse effects are exceedingly rare with appropriate dosing. The theoretical risk of fibrosing colonopathy, a condition characterized by colonic wall thickening and stricture formation, was identified in animal models at doses exceeding 10,000 units/kg/day. In human clinical practice, this risk is minimal at standard therapeutic doses, and no cases have been reported in adult diabetic patients. Nonetheless, clinicians should avoid excessive dose escalation and should document the rationale for high doses when needed.

Future Directions in Research and Clinical Practice

Emerging research aims to refine our understanding of PERT in diabetes. Areas of active investigation include the development of non-porcine enzyme sources (e.g., microbial lipases and recombinant enzymes), which could reduce immunogenicity and expand availability. Clinical trials are also exploring the role of PERT in preventing diabetic complications like malnutrition-related immune dysfunction and sarcopenia. Another promising avenue is the integration of PERT with continuous glucose monitoring (CGM) to quantify the impact of enzyme supplementation on postprandial glycemic excursions in real time. As the evidence base grows, guidelines may incorporate routine EPI screening for people with diabetes who have unexplained gastrointestinal symptoms or weight loss, enabling earlier and more personalized intervention.

Several ongoing clinical trials are specifically examining PERT in diabetes. One large multicenter trial is randomizing type 1 diabetic patients with low fecal elastase levels to PERT or placebo, with primary endpoints of HbA1c reduction and time-in-range on CGM. Another trial is evaluating the impact of PERT on muscle mass and physical function in older adults with type 2 diabetes and confirmed EPI. Results from these studies are expected within the next 2–3 years and may provide the high-quality evidence needed to update clinical practice guidelines.

The development of non-porcine enzyme sources addresses both allergenicity concerns and cultural barriers. Plant-based lipases derived from Aspergillus niger and Rhizopus oryzae have shown promise in early-phase trials, with similar efficacy to porcine-derived products in fat absorption studies. Recombinant human pancreatic enzymes, produced using genetically engineered cell lines, represent another frontier. These products would eliminate the theoretical risk of porcine virus transmission and could be tailored to produce specific enzyme ratios optimized for individual patient needs. While these products are still in development, their eventual availability could expand PERT access to patient populations currently underserved.

The integration of PERT with diabetes technology represents a natural convergence of two therapeutic domains. Smartphone apps that track both enzyme dosing and glucose levels are being developed to help patients identify patterns and optimize timing. Artificial intelligence algorithms that analyze CGM data could potentially alert patients to missed enzyme doses when glucose patterns show unexpected postprandial variability. Closed-loop insulin delivery systems could be programmed with meal-specific enzyme dosing instructions, further personalizing diabetes management. These technological innovations promise to make PERT more accessible, more effective, and better integrated into the daily lives of people with diabetes.

Pancreatic enzyme replacement therapy is a safe, effective, and underrecognized component of comprehensive diabetes management for patients with concurrent exocrine pancreatic insufficiency. By restoring nutrient digestion and absorption, PERT improves weight stability, reduces gastrointestinal discomfort, and contributes to more predictable glycemic control. Clinicians caring for people with diabetes — especially those with type 1 or long-standing type 2 disease — should maintain a low threshold for screening for EPI and consider PERT when clinical signs arise. With proper dosing, timing, and monitoring, PERT can significantly enhance quality of life and metabolic outcomes in appropriately selected patients.

For further reading: NIDDK – Exocrine Pancreatic Insufficiency, American Diabetes Association – Standards of Care, PubMed – PERT in Diabetes and EPI, PMC – Review of PERT in Pancreatic Disease, ADA Guideline on Comprehensive Care.